A double-blind, randomised trial of acyclovir versus placebo was conducted in 31 patients with initial and 85 patients with recurrent genital herpes. 17 patients with initial and 42 with recurrent disease were treated with 200 mg acyclovir by mouth five times a day for 5 days, and the remaining patients received matching placebo. In patients with initial genital herpes shedding virus acyclovir significantly reduced the duration of viral shedding, itching, and pain, the time to crusting and complete healing, and new lesion formation compared with controls. In patients with recurrence disease acyclovir significantly reduced the duration of viral shedding, time to complete healing, and new lesion formation. The reported incidence of adverse events was similar in both acyclovir and placebo groups. Oral acyclovir is effective and well tolerated in patients with initial and recurrent genital herpes and can be used in outpatient therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0140-6736(82)90658-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aseptic meningitis from herpes simplex virus proctitis.
BMJ Case Rep
January 2025
Graduate Medical Education, University of Miami Miller School of Medicine, Fort lauderdale, Florida, USA.
Sexually transmitted proctitis, a prevalent concern among men who have sex with men (MSM) is frequently caused by a range of pathogens, including herpes simplex virus (HSV), and While HSV-associated proctitis typically presents with visible lesions, cases without external manifestations remain evasive. We report the case of an MSM in his early 30s presenting with dyschezia and perineal discomfort after unprotected anoreceptive intercourse. Despite initial inconspicuous findings, rectal swabs revealed HSV-2 infection.
View Article and Find Full Text PDFRelationship Between HSV-1 Serostatus and HSV-2 IgG Confirmation Results Using an Inhibition Assay.
Sex Transm Dis
February 2025
From the Quest Diagnostics Inc., San Juan Capistrano, CA.
Background: Approximately 2% of HerpeSelect herpes simples virus type 2 (HSV-2) IgG enzyme immunoassay (screen assay) sera-positive samples do not confirm using an HSV-2 IgG inhibition assay. Of these, roughly 1.33% are confirmed negative, and a small proportion (0.
View Article and Find Full Text PDFPotential Interactions Between Soil-Transmitted Helminths and Herpes Simplex Virus Type II: Implications for Sexual and Reproductive Health in Sub-Saharan African.
Biology (Basel)
December 2024
Department of Medical Microbiology, College of Health Sciences, School of Laboratory Medicine & Medical Sciences, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban 4001, South Africa.
Sub-Saharan Africa (SSA) bears a disproportionate and overlapping burden of soil-transmitted helminths (STHs) and sexually transmitted viral infections. An estimated 232 million pre-school and school-aged children in SSA are vulnerable to STH infections. Together with this, SSA has a high prevalence of herpes simplex virus type II (HSV-2), the primary cause of genital herpes.
View Article and Find Full Text PDFSeroprevalence of HSV-2 in multiple subgroups of infertile men with abnormal sperm parameters and those seeking sex selection: a case-control study.
BMC Infect Dis
January 2025
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Background: Herpes simplex virus type 2 (HSV-2) is a common sexually transmitted infection (STI) primarily acquired through sexual contact. In 2000, the World Health Organization (WHO) for the first time reported the association of STIs with male infertility. Infertility is described as the inability to achieve a clinical pregnancy after engaging in regular, unprotected sexual intercourse for a year or more.
View Article and Find Full Text PDFA replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in mice.
PLoS One
December 2024
Janssen Vaccines & Prevention, Leiden, The Netherlands.
Herpes Simplex virus (HSV) is the cause of genital herpes and no prophylactic treatment is currently available. Replication-incompetent adenoviral vectors are potent inducers of humoral and cellular immune responses in humans. We have designed an adenoviral vector type 35 (Ad35)-based vaccine encoding the HSV-2 major surface antigen gD2 (Ad35.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!